Jun 1 2007
Oncolytics Biotech Inc. has been granted U.S. Patent 7,223,585 entitled "Viral Purification Methods." The claims cover the production and purification of viruses including reovirus.
"This patent expands our intellectual property portfolio well beyond that of reovirus," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "We have now secured six U.S. patents relating to production or Purification of viruses in addition to the various trade secrets relating to manufacture of our agent."
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.